MGMT and glioblastoma: The use of a molecularly and clinically well‐defined glioblastoma cohort in our analysis aiming to minimize potential selection bias is an important strength of this work compared to previous works evaluating TMT in the field, which suffered from methodological shortcomings, such as heterogeneous patient cohorts and missing key molecular and clinical data (MGMT promoter methylation status, IDH status, information on adjuvant systemic treatment).